Contemporary Management of Acute Coronary Syndromes in the Cardiac Intensive Care Unit: From Rapid Diagnosis to Early Secondary Prevention. (PubMed, J Cardiovasc Dev Dis) - Aug 27, 2026 - "Twelve-month dual antiplatelet therapy remains the default after ACS in patients without high bleeding risk; abbreviated regimens, de-escalation, cangrelor, and combined antiplatelet-anticoagulant treatment are selective strategies...High-intensity statin therapy, with early ezetimibe when needed, is guideline-supported. Early PCSK9 inhibition and low-dose colchicine are selective strategies, whereas SGLT2 inhibitors and GLP-1RAs are established for specific comorbid indications. hs-cTnT Gen 6 and AI-assisted tools remain evidence-evolving, while multiomics and targeted anti-inflammatory therapies remain investigational. Clear separation of guideline-supported, selective, evidence-evolving, and investigational approaches is essential for clinically appropriate ACS care."
Journal • Review • Acute Coronary Syndrome • Cardiovascular • Critical care • Renal Disease
|
|
Atul Pathak; Dan Atar; Domenico Mario Giamundo; Elad Asher; Giuseppe Andò; Mamas A Mamas; Marco Bernardi; Mirvat Alasnag; Pierre Sabouret; Salvatore De Rosa; Stefano Figliozzi
|